CoChat
Sign Up
Cited by 5

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth

Huynh, Tony, Murray, Jayne, Flemming, Claudia L., Kamili, Alvin, Hofmann, Ute, Cheung, Leanna, Roundhill, Elizabeth A., Yu, Denise M.T., Webber, Hannah T., Schwab, Matthias, Henderson, Michelle J., Haber, Michelle, Norris, Murray D., Fletcher, Jamie I.·2020·Biochemical Pharmacology
DOI 10.1016/j.bcp.2019.113770
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2019.113770

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 31

  1. Zaza, 2005, Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment, Blood, 106, 1778, 10.1182/blood-2005-01-0143 · DOI
  2. Ruel, 2019, Characterization of 6-Mercaptopurine transport by the SLC43A3-encoded nucleobase transporter, Mol. Pharmacol., 95, 584, 10.1124/mol.118.114389 · DOI
  3. Meyer, 2013, Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia, Nat. Genet., 45, 290, 10.1038/ng.2558 · DOI
  4. Tzoneva, 2013, Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL, Nat. Med., 19, 368, 10.1038/nm.3078 · DOI
  5. Li, 2015, Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL, Nat. Med., 21, 563, 10.1038/nm.3840 · DOI
  6. Wielinga, 2002, Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells, Mol. Pharmacol., 62, 1321, 10.1124/mol.62.6.1321 · DOI
  7. Krishnamurthy, 2008, Transporter-mediated protection against thiopurine-induced hematopoietic toxicity, Cancer Res., 68, 4983, 10.1158/0008-5472.CAN-07-6790 · DOI
  8. Norris, 2005, Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro, Mol. Cancer Ther., 4, 547, 10.1158/1535-7163.MCT-04-0161 · DOI
  9. Tian, 2005, Human multidrug resistance associated protein 4 confers resistance to camptothecins, Pharm. Res., 22, 1837, 10.1007/s11095-005-7595-z · DOI
  10. Murray, 2017, Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo, Eur. J. Cancer, 83, 132, 10.1016/j.ejca.2017.06.024 · DOI
  11. Cheung, 2015, Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen, Biochem. Pharmacol., 93, 380, 10.1016/j.bcp.2014.11.006 · DOI
  12. Ciccarone, 1989, Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages, Cancer Res., 49, 219
  13. Cheng, 2007, Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma, Eur. J. Cancer, 43, 1467, 10.1016/j.ejca.2007.03.008 · DOI
  14. Cheung, 2014, High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4), Biochem. Pharmacol., 91, 97, 10.1016/j.bcp.2014.05.023 · DOI · Paper page
  15. Boss, 1982, Decreased purine synthesis during amino acid starvation of human lymphoblasts, J. Biol. Chem., 257, 4242, 10.1016/S0021-9258(18)34712-4 · DOI
  16. Burkhart, 2009, Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma, Cancer Res., 69, 6573, 10.1158/0008-5472.CAN-09-1075 · DOI
  17. Schneider, 2012, NIH Image to ImageJ: 25 years of image analysis, Nat. Methods, 9, 671, 10.1038/nmeth.2089 · DOI · Paper page
  18. Weiss, 1997, Targeted expression of MYCN causes neuroblastoma in transgenic mice, EMBO J., 16, 2985, 10.1093/emboj/16.11.2985 · DOI
  19. Hofmann, 2012, Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometry, Anal. Chem., 84, 1294, 10.1021/ac2031699 · DOI
  20. Moriyama, 2016, NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity, Nat. Genet., 48, 367, 10.1038/ng.3508 · DOI
  21. Henderson, 2011, ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux, J. Natl Cancer Inst., 103, 1236, 10.1093/jnci/djr256 · DOI
  22. Vogt, 1993, The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts, Biochim. Biophys. Acta, 1181, 189, 10.1016/0925-4439(93)90110-M · DOI
  23. Neurath, 2005, 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn’s disease, Clin. Gastroenterol. Hepatol., 3, 1007, 10.1016/S1542-3565(05)00697-X · DOI
  24. Relling, 1999, Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus, J. Natl. Cancer Inst., 91, 2001, 10.1093/jnci/91.23.2001 · DOI
  25. Stanulla, 2005, Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia, JAMA, 293, 1485, 10.1001/jama.293.12.1485 · DOI
  26. Brouwer, 2005, Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment, Clin. Chim. Acta, 361, 95, 10.1016/j.cccn.2005.05.006 · DOI
  27. Starling, 1974, Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) alone; vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaptopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone, Cancer Chemother. Rep., 58, 683
  28. Zimm, 1985, Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion, Cancer Res., 45, 1869
  29. Fulda, 1995, Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro, Eur. J. Cancer, 31a, 616, 10.1016/0959-8049(95)00055-N · DOI
  30. Dieck, 2019, Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL, Blood, 133, 2263, 10.1182/blood-2019-01-852392 · DOI
  31. Lau, 2015, MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma, Oncotarget, 6, 15510, 10.18632/oncotarget.3732 · DOI

Cited by

Sorted by citations

See all 5

Metadata

Authors
Huynh, T., Murray, J., Flemming, C. L., Kamili, A., Hofmann, U., Cheung, L., Roundhill, E. A., Yu, D. M. T., Webber, H. T., Schwab, M., Henderson, M. J., Haber, M., Norris, M. D., & Fletcher, J. I.
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2020-02
Volume
172
Pages
113770
ISSN
0006-2952
DOI
10.1016/j.bcp.2019.113770
Cited by
5
References
1
Language
en
Licence
Funders
  • Cancer Institute NSW
  • National Health and Medical Research Council
  • Robert Bosch Stiftung

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review